LY4006896 is a novel therapeutic candidate developed by [Eli Lilly and Company](https://www.lilly.com) currently undergoing evaluation in a Phase 1 clinical trial for [Parkinson's disease](/diseases/parkinsons-disease)[@kalia_2015]. This trial represents Eli Lilly's strategic entry into Parkinson's disease drug development, expanding beyond their established Alzheimer's disease pipeline["@lilly_neuro"].
...
Overview
Mermaid diagram (expand to render)
LY4006896 is a novel therapeutic candidate developed by [Eli Lilly and Company](https://www.lilly.com) currently undergoing evaluation in a Phase 1 clinical trial for [Parkinson's disease](/diseases/parkinsons-disease)[@kalia_2015]. This trial represents Eli Lilly's strategic entry into Parkinson's disease drug development, expanding beyond their established Alzheimer's disease pipeline["@lilly_neuro"].
Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 10 million people worldwide["@jankovic_2020"]. The disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to the classic motor symptoms including bradykinesia, resting tremor, rigidity, and postural instability["@bargmann_2013"].
Trial Details
| Parameter | Value | |-----------|-------| | Trial ID | NCT06809400 | | Sponsor | Eli Lilly and Company | | Phase | Phase 1 | | Status | Recruiting | | Study Type | Interventional | | Indication | Parkinson's Disease | | Start Date | 2024 |
Trial Design
Phase 1 trials represent the first human testing of a new therapeutic compound and primarily focus on safety and tolerability[@postma_2024]. The design typically includes:
Dose-Escalation Phase
Single ascending dose (SAD) cohort
Multiple ascending dose (MAD) cohort
Safety monitoring at each dose level
Pharmacokinetic sampling
Study Objectives
Evaluate safety and tolerability in Parkinson's disease patients
Characterize pharmacokinetic profile
Identify maximum tolerated dose (MTD)
Assess preliminary pharmacodynamic signals
Mechanism of Action
While the specific molecular mechanism of LY4006896 remains proprietary, Eli Lilly's neuroscience division has been exploring several pathways relevant to Parkinson's disease pathogenesis:
Alpha-Synuclein Targeting
[Alpha-synuclein](/proteins/alpha-synuclein) is a key protein implicated in Parkinson's disease pathogenesis[@timmons_2018]. Abnormal aggregation of alpha-synuclein into Lewy bodies represents a pathological hallmark of the disease. Therapeutic strategies targeting alpha-synuclein include:
Monoclonal antibodies against alpha-synuclein
Small molecules inhibiting aggregation
Gene therapy approaches
Neuroprotection
Eli Lilly has established expertise in neuroprotective strategies through their Alzheimer's disease programs. Similar approaches may be applied to Parkinson's disease:
Anti-apoptotic signaling modulation
Growth factor support
Cellular stress response enhancement
Mitochondrial Function
[Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) plays a central role in dopaminergic neuron degeneration[@schapira_2013]. Therapeutic targets include:
Complex I activity restoration
Oxidative stress reduction
Mitochondrial dynamics normalization
Neuroinflammation Modulation
[Neuroinflammation](/mechanisms/neuroinflammation) contributes to disease progression through microglial activation and cytokine release[@lin_2019]. Anti-inflammatory approaches include:
Microglial activation inhibition
Cytokine blockade
Complement system modulation
Clinical Development Context
Eli Lilly's Neuroscience Portfolio
Eli Lilly has built a significant neuroscience pipeline targeting neurodegenerative diseases:
Current Parkinson's disease treatments provide symptomatic relief but do not slow or halt disease progression. LY4006896 represents an attempt to develop disease-modifying therapies addressing: